Dr. D'Amato on the Utility of NGS in Stage I, II, and III Sarcoma

Partner | Cancer Centers | <b>Sylvester Comprehensive Cancer Center</b>

Gina Z. D'Amato, MD, discusses the utility of next-generation sequencing in patients with stage I, II, or III sarcoma.

Gina Z. D'Amato, MD, associate professor and assistant director of Clinical Research, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the utility of next-generation sequencing (NGS) in patients with stage I, II, or III sarcoma.

The use of NGS in this patient population largely depends on the sarcoma subtype being treated, D’Amato says. Moreover, some subtypes have different sensitivities to treatments.

In patients with stage I, II, or III sarcomas, standard surgical intervention and radiation therapy, with or without chemotherapy, are used with curative intent, explains D’Amato.

As such, NGS is unnecessary in this setting as there are no data to inform whether patients may benefit from adjuvant targeted therapies, concludes D’Amato.